Sevelamer is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease; consists of polyallylamine that is crosslinked with epichlorohydrin.

Setrobuvir (ANA-598) is an experimental drug candidate For the treatment of hepatitis C. It was discovered at Anadys Pharmaceuticals. In 2011, Roche acquired Anadys in order to develop setrobuvir. It is currently in Phase IIb clinical trials, used in combination with interferon and ribavirin, targeting hepatitis C patients with genotype 1.For the detailed information of Setrobuvir, the solubility of Setrobuvir in water, the solubility of Setrobuvir in DMSO, the solubility of Setrobuvir in PBS buffer, the animal experiment (test) of Setrobuvir, the cell expriment (test) of Setrobuvir, the in vivo, in vitro and clinical trial test of Setrobuvir, the EC50, IC50,and Affinity of Setrobuvir, Please contact DC Chemicals..

Setafrastat is a small molecule hair growth stimulator.

Sermorelin is a Growth Hormone Releasing Hormone (GHRH) produced by the brain that stimulates the production and release of Growth Hormone (GH).

Serdexmethylphenidate is the dextrorotary form of methylphenidate and a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant..

SERCA2a activator A is a novel sarco/endoplasmic reticulum Ca2+-dependent ATPase 2a (SERCA2a) activator that activates the Ca2+-dependent ATPase activity of cardiac SR vesicles but not that of skeletal muscle SR vesicles that lack of phospholamban (PLN).

Seratrodast(AA 2414) is a potent and selective thromboxane A2 receptor (TP) antagonist.

Senktide is a potent, selective agonist of neuromedin K3 (NK3) receptor (EC50 =0.5-3 nM), less potently agonizes the NK1 receptor (EC50=35 µM) and is without effect on the NK2 receptor..

SEN1269 is a novel potent Aβ aggregation inhibitor that binds to monomeric Aβ1-42 with Kd of 4.4 uM, protects neuronal cell lines against an Aβ1-42 insult with IC50 of 15 uM.

Sembragiline (RO4602522, RG1577, EVT 302) is a novel potent, selective, orally available monoamine oxidase B (MAO-B) inhibitor with IC50 of 5.9 nM, >600-fold selectivity over MAO-A.

Semapimod (CNI 1493.

Semapimod (CNI 1493.

Selurampanel (BGG 492) is a selective, orally active and competitive AMPA receptor (AMPAR) antagonist with IC50 of 0.19 uM.

Selgantolimod is a novel toll-​like receptor TLR8 modulator for the treatment of HIV infection..

SEL24-B489 (SEL24) is a potent, dual PIM and FLT3-ITD inhibitor with Kd of 2/2/3 nM for PIM1/2/3, Kd of 160/16 nM for FLT3-WT/FLT3-ITD, respectively.

SEL24-B489 (SEL24) is a potent, dual PIM and FLT3-ITD inhibitor with Kd of 2/2/3 nM for PIM1/2/3, Kd of 160/16 nM for FLT3-WT/FLT3-ITD, respectively.

SEL120-34A is an ATP-competitive, selective, orally active CDK8 inhibitor that inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50 of 4.4 nM and 10.4 nM, respectively.

SEL120-34A is an ATP-competitive, selective, orally active CDK8 inhibitor that inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50 of 4.4 nM and 10.4 nM, respectively.

Seco-rapamycin is the first in vivo open-ring metabolite of rapamycin that does not affect mTOR..

Secnidazole (Flagentyl)

SecinH3 is a selective cytohesin inhibitor with IC50 of 2.4 μM, 5.4 μM, 5.4 μM, 5.6 μM, 5.6 μM, and 65 μM for hCyh2, hCyh1, mCyh3, hCyh3, drosophila steppke, and yGea2-S7, respectively.

SDZ 220-581 is a potent, competitive NMDA receptor antagonist with pKi of 7.7, fully protects against maximal electroshock seizures (MES) at oral doses of 10 mg/kg in rats and in mice. .

SD-1029 (NSC 371488) is a potent inhibitor of Stat3 activation, suppresses EGFP-Stat3 nuclear translocation at 10 uM in both BHK-21 and U2-OS cells.

Scytonemin is a marine natural product that inhibits PLK1 with IC50 of 2 uM against recombinant enzyme, shows similar potentcy for Myt1, Chk1,Cdk1/cyclin B and PKCβ2, less potent against PKA and Tie2.

Sclerotigenin is a natural diazepine originally isolated from P. sclerotigenum that acts as an insect growth regulator.1 It reduces the growth rate of first instar H. zea larvae by 42% relative to controls when administered in the standard test diet at 20

SCH 900229 is a potent and presenilin 1 selective, and orally active inhibitor of γ-secretase (Aβ40 IC50=1.3 nM).

SCH 412348 is a potent and highly selective A2A receptor competitive antagonist with Ki of 0.6 nM.

SC-68448 (SC68448) is a potent, selective peptidomimetic antagonist of the integrin αvβ3 with IC50 of 1 nM, 100-fold selectivity over αIIbβ3.

S-C025 is a highly potent antagonist of oxoeicosanoid receptor (OXE receptor) with IC50 of 0.12 nM.

S-C025 is a highly potent antagonist of oxoeicosanoid receptor (OXE receptor) with IC50 of 0.12 nM, inhibits 5-oxo-ETE-induced calcium mobilization in human neutrophils..